The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | The promise of brentuximab vedotin for the treatment of pediatric HL
Kara Kelly, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares some results from a Phase III trial investigating the efficacy of brentuximab vedotin plus chemotherapy versus standard of care in children and adolescents with Hodgkin lymphoma. Dr Kelly highlights the improved event-free survival (EFS) observed, and further comments on the excitement surrounding these results and the promise of brentuximab vedotin for the treatment of HL. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
